Cirrhosis screening and earlier detection
Finding advanced fibrosis before symptoms appear changes surveillance and specialist planning. This page explains where elastography fits — and where its limits are.
Why earlier detection matters
Detecting cirrhosis before overt decompensation changes the pathway: hepatocellular carcinoma (HCC) surveillance, portal hypertension workup, specialist urgency, and long-term monitoring all shift. Advanced fibrosis detection is therefore a core goal of modern non-invasive staging.
How screening usually works
Pathways often start with clinical risk factors and blood-based scores, then move to elastography when risk remains uncertain or when advanced disease needs to be ruled in or out more confidently. See fibrosis staging F0–F4 and the FIB-4 calculator.
Limits to understand
Elastography is most useful in screening, staging, and compensated disease pathways. Performance can be limited in decompensated cirrhosis with ascites. Your clinician will choose the right test for your situation.
If results suggest advanced disease
Higher stiffness values usually prompt specialist involvement and a broader liver workup. Exact thresholds vary by disease cause — use disease-specific context, not a single universal number.
Frequently asked questions
Can you have cirrhosis without symptoms?
Yes. Compensated cirrhosis can be quiet for a long time. That is why staging pathways focus on finding advanced fibrosis before late complications appear.
Does elastography diagnose cirrhosis on its own?
Elastography estimates stiffness and helps identify people who may have advanced fibrosis or cirrhosis. Results are interpreted with history, blood tests, imaging, and specialist judgement — not as a standalone diagnosis.
What happens if advanced fibrosis is found?
Your care team may recommend closer monitoring, specialist review, and in some cases surveillance for liver cancer. Exact next steps depend on the cause and your overall health.